Age-Related Macular Degeneration Quality of Life Scale
Also known as: AMD-QoL, Macular QoL
The AMD Quality of Life (AMD-QoL) scale is a disease-specific instrument designed to measure the impact of age-related macular degeneration on patient-reported health-related quality of life. Developed by Mitchell, Bradley, and colleagues (2005), the AMD-QoL addresses concerns unique to macular disease: central vision loss, reading difficulty, facial recognition, driving impairment, and emotional burden. It serves as a primary or secondary outcome in AMD clinical trials and informs patient-centered care decisions.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Appropriate for any patient with AMD diagnosis (dry AMD, wet AMD with or without active CNV) to document baseline functional and emotional impact. Useful in early/mild AMD to assess whether current QoL justifies preventive therapy. Essential pre- and post-treatment (anti-VEGF initiation, switch of agent, laser therapy) to measure subjective benefit. Recommended at baseline and 3–6 month intervals in longitudinal AMD management to track disease trajectory and treatment response. Helps distinguish stable visual acuity from declining QoL due to disease progression, treatment burden, or comorbidities (depression, other eye disease).
Strengths & limitations
- Disease-specific: items directly address macular loss concerns (reading, facial recognition, central vision scotoma), more sensitive than generic vision instruments in AMD populations
- Multidimensional: captures functional, emotional, and social domains; not limited to activity/acuity scores
- Responsive to treatment: validates anti-VEGF therapy and rehabilitation benefit in AMD RCTs; correlates with patient-perceived improvement or deterioration
- Appropriate for older populations: developed for AMD (median age 70–80), avoiding age-related bias of some vision instruments
- Psychometrically sound: good internal consistency (Cronbach α 0.75–0.90), test-retest reliability (ICC >0.70), and discriminant validity (AMD vs. no AMD)
- Multiple versions exist with varying item counts and structures: published literature includes AMD-Catarct Symptom Effect Questionnaire (ACSEQ), AMD-QoL, and related variants; exact instrument must be specified to ensure comparability
- Moderate ceiling effects in mild/early AMD: some questions may not apply or show limited variability in vision >20/40
- Limited to English in most validation; translation and validation in other languages less extensive than VFQ-25
- Does not distinguish active CNV from quiescent AMD or dry from wet disease: different disease trajectories may produce different QoL patterns but are not separately scored
- Moderately correlated with visual acuity (r ~0.5–0.7); some patients with same acuity report widely different QoL due to scotoma location, adaptation, or psychological factors
Frequently asked
How does AMD-QoL relate to visual acuity in predicting treatment benefit?
AMD-QoL and acuity are moderately correlated but discordant in some patients. A patient with acuity 20/40 may have high AMD-QoL impairment if scotoma is large and central; conversely, acuity 20/60 with small paracentral scotoma may yield modest AMD-QoL score. Treatment decisions should weigh both acuity and AMD-QoL alongside OCT findings and patient goals.
What AMD-QoL score improvement is expected after anti-VEGF injection initiation?
Expected improvement ranges 5–15 points on a 0–100 scale over 3–6 months if vision stabilizes or improves, corresponding to modest emotional and functional gain. Larger improvements (15–25 points) occur if acuity improves by ≥2 lines. If acuity is stable, psychological reassurance (stopping decline) may yield 5–10 point improvement.
Is AMD-QoL useful in dry AMD, or is it only for wet AMD?
AMD-QoL is valid in both dry and wet AMD. Dry AMD with extensive drusen and functional impact (reading difficulty, glare) produces high AMD-QoL scores. Wet AMD with active CNV may show lower baseline scores; anti-VEGF stabilization yields QoL improvement. AMD-QoL tracks disease burden in both forms.
Can AMD-QoL be used in patients with monocular AMD or bilateral disease?
AMD-QoL addresses overall functional vision; most items do not specify eye. In monocular CNV with healthy fellow eye, AMD-QoL is often low (good function preserved). Bilateral AMD or monocular disease with fellow-eye comorbidity (cataract, optic neuropathy) yields higher AMD-QoL scores reflecting combined burden. Clinical context clarifies.
Sources
- Mitchell, J., Bradley, C., Anderson, S. J., et al. (2005). Perceived impact of retinal impairment on quality of life: the AMD and Cataract Symptom Effect Questionnaire. Health Qual Life Outcomes, 3(1), 12. DOI: 10.1186/1477-7525-3-25 ↗
- Submacular Surgery Trials (SST) Research Group. (2004). Quality of life in patients with subfoveal choroidal neovascularization due to age-related macular degeneration. Arch Ophthalmol, 122(11), 1635-1645. link ↗
How to cite this page
ScholarGate. (2026, June 3). Age-Related Macular Degeneration Quality of Life Scale. ScholarGate. https://scholargate.app/en/ophthalmology/amd-quality-of-life
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- IVIOphthalmology↔ compare
- LVQOLOphthalmology↔ compare
- NEI-VFQ-25Ophthalmology↔ compare
- VF-14Ophthalmology↔ compare